According to Alexander Gintsburg, scientists at Russia’s Gamaleya Center have finished pre-clinical testing of a nasal spray COVID-19 vaccine and are prepared to start clinical trials, TASS reports.
Preclinical studies for the nasal spray vaccination have been completed, and significant progress has been achieved. He stated that they are prepared to move forward with clinical studies. The Sputnik V vaccine’s second component, according to Gintsburg, is, in fact, the nasal spray vaccination.
Clinical trials should start by the end of 2021 or the beginning of 2022, according to the head of the Gamaleya Center, and the vaccine is likely to be authorized in 2022.